This morning, we will discuss our fourth quarter and full year 2011 financial results, provide 2012 guidance, update you on our Genzyme Genetics integration, highlight our progress on our 5-pillar strategy and provide answers to several frequently asked questions.

I'd now like to turn the call over to Steve Anderson, who has a few comments before we begin

Stephen Anderson

Before we get started, I would like to point out that there will be a replay of this conference call available via the telephone and Internet. Please refer to today's press release for replay information.

This morning, the company filed a Form 8-K that included additional information on our business and operations. This information is also available on our website. Analysts and investors are directed to this 8-K and our website to review this supplemental information. Additionally, we refer you to today's press release, which is available on our website for a reconciliation of non-GAAP financial measures discussed during today's call to GAAP. These non-GAAP measures include adjusted EPS excluding amortization, free cash flow and adjusted operating income.

I would also like to point out that we are making forward-looking statements during this conference call. These forward-looking statements include, among others, statements about our expected financial results, the implementation of our business strategy and the ongoing benefits of the Genzyme Genetics and other acquisitions. These statements are based upon current expectations and are subject to change based upon various factors that could affect the company's financial results. Some of these factors are set forth in detail in our 2010 10-K and subsequent filings. The company has no obligation to provide any updates to these forward-looking statements, even if our expectations change.

Now, Brad Hayes will review our financial results.

William B. Hayes

Thank you, Steve. On today's call, I will review 4 key measures of our financial performance: cash flow, revenue growth, margin and liquidity. I'll also review our 2012 guidance.

If you liked this article you might like

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Amid M&A Buzz, LabCorp CEO Says Deal Pipeline 'Very Healthy'

INC Research Holdings Seen as Likely LabCorp. Takeover Target

5 Big Stocks to Buy for Big Gains

Laboratory Corp Of America Holdings (LH) Hits New Lifetime High Today